Zacks: Analysts Expect Brainstorm Cell Therapeutics Inc. (BCLI) Will Announce Earnings of -$0.10 Per Share

Wall Street brokerages expect Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) to report earnings of ($0.10) per share for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Brainstorm Cell Therapeutics’ earnings. Brainstorm Cell Therapeutics reported earnings of ($0.09) per share in the same quarter last year, which suggests a negative year over year growth rate of 11.1%. The firm is expected to report its next quarterly earnings results on Monday, November 13th.

On average, analysts expect that Brainstorm Cell Therapeutics will report full-year earnings of ($0.38) per share for the current financial year. For the next financial year, analysts anticipate that the firm will report earnings of ($0.42) per share. Zacks’ EPS calculations are an average based on a survey of research analysts that cover Brainstorm Cell Therapeutics.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last released its quarterly earnings results on Monday, August 14th. The biotechnology company reported ($0.06) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.10) by $0.04.

This article was originally published by and is the sole property of Zolmax. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://zolmax.com/investing/zacks-analysts-expect-brainstorm-cell-therapeutics-inc-bcli-will-announce-earnings-of-0-10-per-share/1654509.html

Several brokerages recently issued reports on BCLI. Maxim Group set a $8.00 price target on Brainstorm Cell Therapeutics and gave the stock a “buy” rating in a report on Tuesday, June 13th. ValuEngine downgraded Brainstorm Cell Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, July 14th.

A number of institutional investors have recently made changes to their positions in the business. Sphera Funds Management LTD. bought a new stake in Brainstorm Cell Therapeutics during the 2nd quarter valued at $2,759,000. Vanguard Group Inc. raised its stake in Brainstorm Cell Therapeutics by 2.8% during the 2nd quarter. Vanguard Group Inc. now owns 657,101 shares of the biotechnology company’s stock valued at $2,733,000 after acquiring an additional 17,657 shares in the last quarter. Finally, KCG Holdings Inc. raised its stake in Brainstorm Cell Therapeutics by 4.6% during the 1st quarter. KCG Holdings Inc. now owns 41,537 shares of the biotechnology company’s stock valued at $177,000 after acquiring an additional 1,820 shares in the last quarter. 12.74% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “Zacks: Analysts Expect Brainstorm Cell Therapeutics Inc. (BCLI) Will Announce Earnings of -$0.10 Per Share” was reported by Zolmax and is the property of of Zolmax. If you are reading this story on another site, it was illegally copied and reposted in violation of US and international copyright & trademark laws. The correct version of this story can be accessed at https://zolmax.com/investing/zacks-analysts-expect-brainstorm-cell-therapeutics-inc-bcli-will-announce-earnings-of-0-10-per-share/1654509.html.

Brainstorm Cell Therapeutics (NASDAQ BCLI) traded down 2.34% during midday trading on Friday, hitting $4.17. The stock had a trading volume of 38,849 shares. The firm’s market cap is $78.24 million. The stock has a 50-day moving average price of $4.23 and a 200 day moving average price of $4.19. Brainstorm Cell Therapeutics has a one year low of $2.06 and a one year high of $5.18.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.

Get a free copy of the Zacks research report on Brainstorm Cell Therapeutics (BCLI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Brainstorm Cell Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Bombardier, Inc.  Given a C$3.25 Price Target by Raymond James Financial, Inc. Analysts
Bombardier, Inc. Given a C$3.25 Price Target by Raymond James Financial, Inc. Analysts
TD Securities Trims TMAC Resources Inc  Target Price to C$15.00
TD Securities Trims TMAC Resources Inc Target Price to C$15.00
Imperial Metals Corp  PT Set at C$3.00 by Scotiabank
Imperial Metals Corp PT Set at C$3.00 by Scotiabank
Equity One  & The Competition Head-To-Head Contrast
Equity One & The Competition Head-To-Head Contrast
Head-To-Head Review: Versum Materials  and Minerals Technologies
Head-To-Head Review: Versum Materials and Minerals Technologies
Zacks: Brokerages Expect Service Corporation International  Will Post Quarterly Sales of $736.69 Million
Zacks: Brokerages Expect Service Corporation International Will Post Quarterly Sales of $736.69 Million


Leave a Reply

 
© 2006-2017 Zolmax.